Hyperfractionated Irradiation with 3 Cycles of Induction Chemotherapy in Stage IIIA-N2 Lung Cancer

被引:7
作者
Chen, Fengshi [1 ]
Okubo, Kenichi [1 ]
Sonobe, Makoto [1 ]
Shibuya, Keiko [2 ]
Matsuo, Yukinori [2 ]
Kim, Young Hak [3 ]
Yanagihara, Kazuhiro [4 ]
Bando, Toru [1 ]
Date, Hiroshi [1 ]
机构
[1] Kyoto Univ, Dept Thorac Surg, Sakyo Ku, Kyoto 6068507, Japan
[2] Kyoto Univ, Dept Radiat Oncol & Image Appl Therapy, Sakyo Ku, Kyoto 6068507, Japan
[3] Kyoto Univ, Dept Resp Med, Sakyo Ku, Kyoto 6068507, Japan
[4] Kyoto Univ, Outpatient Oncol Unit, Kyoto 6068507, Japan
关键词
PHASE-II TRIAL; RANDOMIZED CONTROLLED-TRIAL; SOUTHWEST-ONCOLOGY-GROUP; NEOADJUVANT CHEMORADIOTHERAPY; THERAPY; RADIOTHERAPY; RESECTION; RADIATION; CHEMORADIATION; CARBOPLATIN;
D O I
10.1007/s00268-012-1747-1
中图分类号
R61 [外科手术学];
学科分类号
摘要
The purpose of the present study was to improve the prognosis of patients with stage IIIA-N2 non-small cell lung cancer (NSCLC). To achieve that goal, we performed induction chemoradiotherapy followed by surgery. The criteria for this phase II study were a parts per thousand currency sign75-year-old patients with pathologically diagnosed stage IIIA-N2 NSCLC who had performance statuses of 0 or 1 with good organ function. Three cycles of chemotherapy with paclitaxel and carboplatin were carried out, with concurrent hyperfractionated irradiation (42 Gy). After re-evaluation, pulmonary resections were considered unless patients showed progressive disease. The primary endpoint was overall survival (OS), and the secondary endpoints were disease-free survival (DFS) and absence of toxicity. All 22 patients enrolled in this study completed the induction chemoradiotherapy without any severe complications. In these 22 patients, the 2- and 5-year OS were 81 and 47 %, respectively. There were no therapy-related deaths. Surgery was subsequently performed in 19 patients (86 %). Pathological complete responses were seen in 6 patients (27 %), while node downstaging was obtained in 10 patients (45 %). In the 19 patients who underwent surgery, the 2- and 5-year OS rates were 83 and 62 %, respectively, and the 2-year DFS rate was 63 %. All 6 patients with pathological complete responses survived without disease. Patients with residual multiple-station N2 showed worse OS and DFS rates than did those with downstaged and single-station N2 (P = 0.026 and P < 0.0001, respectively). This trimodal therapy was effective and well tolerated, and it is an acceptable therapeutic option for patients with locally advanced stage IIIA-N2 NSCLC. Patients without persistent multiple-station N2 showed promising survival.
引用
收藏
页码:2858 / 2864
页数:7
相关论文
共 23 条
[1]   Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial [J].
Albain, Kathy S. ;
Swann, R. Suzanne ;
Rusch, Valerie W. ;
Turrisi, Andrew T., III ;
Shepherd, Frances A. ;
Smith, Colum ;
Chen, Yuhchyau ;
Livingston, Robert B. ;
Feins, Richard H. ;
Gandara, David R. ;
Fry, Willard A. ;
Darling, Gail ;
Johnson, David H. ;
Green, Mark R. ;
Miller, Robert C. ;
Ley, Joanne ;
Sause, Willliam T. ;
Cox, James D. .
LANCET, 2009, 374 (9687) :379-386
[2]   CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805 [J].
ALBAIN, KS ;
RUSCH, VW ;
CROWLEY, JJ ;
RICE, TW ;
TURRISI, AT ;
WEICK, JK ;
LONCHYNA, VA ;
PRESANT, CA ;
MCKENNA, RJ ;
GANDARA, DR ;
FOSMIRE, H ;
TAYLOR, SA ;
STELZER, KJ ;
BEASLEY, KR ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1880-1892
[3]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[4]   Randomized phase III trial comparing cisplatin-etoposide to carhoplatin-paclitaxel in advanced or metastatic non-small cell lung cancer [J].
Belani, CP ;
Lee, JS ;
Socinski, MA ;
Robert, F ;
Waterhouse, D ;
Rowland, K ;
Ansari, R ;
Lilenbaum, R ;
Natale, RB .
ANNALS OF ONCOLOGY, 2005, 16 (07) :1069-1075
[5]   Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer [J].
Choi, NC ;
Carey, RW ;
Daly, W ;
Mathisen, D ;
Wain, J ;
Wright, C ;
Lynch, T ;
Grossbard, M ;
Grillo, H .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :712-722
[6]   Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer:: Mature results of a phase II trial [J].
Eberhardt, W ;
Wilke, H ;
Stamatis, G ;
Stuschke, M ;
Harstrick, A ;
Menker, H ;
Krause, B ;
Müeller, MR ;
Stahl, M ;
Flasshove, M ;
Budach, V ;
Greschuchna, D ;
Konietzko, N ;
Sack, H ;
Seeber, S .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :622-634
[7]   Multimodality therapy for stage III non-small-cell lung cancer [J].
Farray, D ;
Mirkovic, N ;
Albain, KS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (14) :3257-3269
[8]   Phase II Trial of a Trimodality Regimen for Stage III Non-Small-Cell Lung Cancer Using Chemotherapy As Induction Treatment With Concurrent Hyperfractionated Chemoradiation With Carboplatin and Paclitaxel Followed by Subsequent Resection: A Single-Center Study [J].
Friedel, Godehard ;
Budach, Wilfried ;
Dippon, Juergen ;
Spengler, Werner ;
Eschmann, Susanne Martina ;
Pfannenberg, Christina ;
Al-Kamash, Fawaz ;
Walles, Thorsten ;
Aebert, Hermann ;
Kyriss, Thomas ;
Veit, Stefanie ;
Kimmich, Martin ;
Bamberg, Michael ;
Kohlhaeufl, Martin ;
Steger, Volker ;
Hehr, Thomas .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) :942-948
[9]   Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial [J].
Girard, Nicolas ;
Mornex, Francoise ;
Douillard, Jean-Yves ;
Bossard, Nadine ;
Quoix, Elisabeth ;
Beckendorf, Veronique ;
Grunenwald, Dominique ;
Amour, Elodie ;
Milleron, Bernard .
LUNG CANCER, 2010, 69 (01) :86-93
[10]   Induction chemoradiotherapy for advanced stage III non-small cell lung cancer: long-term follow-up in 42 patients [J].
Katakami, N ;
Okazaki, M ;
Nishiuchi, S ;
Fukuda, H ;
Horikawa, T ;
Nishiyama, H ;
Inui, H ;
Bando, K .
LUNG CANCER, 1998, 22 (02) :127-137